Лекарственные поражения печени (ЛПП) у взрослых

1. Chalasani N.P., Maddur H., Russo M.W., Wong R.J., Reddy K.R.; Practice Parameters Committee of the American College of Gastroenterology. ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. Am J Gastroenterol. 2021 May 1;116(5):878-898. doi: 10.14309/ajg.0000000000001259.

2. Brennan P.N., Cartlidge P., Manship T., Dillon J.F. Guideline review: EASL clinical practice guidelines: drug-induced liver injury (DILI). Frontline Gastroenterol. 2021 Jul 29;13(4):332-336. doi: 10.1136/flgastro-2021-101886.

3. Ivashkin V.T., Baranovsky A. Yu., Raikhelson K.L. et al. Drug-Induced Liver Injuries (Clinical Guidelines for Physicians). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(1):85-115. (In Russ.) doi: 10.22416/1382-4376-2019-29-1-101-131.@@ Ивашкин В.Т., Барановский А.Ю., Райхельсон К.Л. и др. Лекарственные поражения печени (клинические рекомендации для врачей). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;29(1):101-131. doi: 10.22416/1382-4376-2019-29-1-101-131.

4. Björnsson E.S., Hoofnagle J.H. Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports. Hepatology. 2016 Feb;63(2):590-603. doi: 10.1002/hep.28323.

5. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019 Jun;70(6):1222-1261. doi: 10.1016/j.jhep.2019.02.014.

6. Fontana R.J., Liou I., Reuben A., Suzuki A., Fiel M.I., Lee W., Navarro V. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology. 2023 Mar 1;77(3):1036-1065. doi: 10.1002/hep.32689.

7. Wang J., Ma Z., Niu M. et al. Evidence chain-based causality identification in herb-induced liver injury: exemplification of a well-known liver-restorative herb Polygonum multiflorum. Front Med. 2015 Dec;9(4):457-67. doi: 10.1007/s11684-015-0417-8.

8. Byeon J.H., Kil J.H., Ahn Y.C., Son C.G. Systematic review of published data on herb induced liver injury. J Ethnopharmacol. 2019 Apr 6;233:190-196. doi: 10.1016/j.jep.2019.01.006.

9. Zoubek M.E., Lucena M.I., Andrade R.J., Stephens C. Systematic review: ibuprofen-induced liver injury. Aliment Pharmacol Ther. 2020 Mar;51(6):603-611. doi: 10.1111/apt.15645.

10. Björnsson E.S. Hepatotoxicity by Drugs: The Most Common Implicated Agents. Int J Mol Sci. 2016 Feb 6;17(2):224. doi: 10.3390/ijms17020224.

11. Gaedigk A., Ingelman-Sundberg M., Miller N.A., Leeder J.S., Whirl-Carrillo M., Klein T.E.; PharmVar Steering Committee. The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database. Clin Pharmacol Ther. 2018 Mar;103(3):399-401. doi: 10.1002/cpt.910.

12. Björnsson H.K., Björnsson E.S. Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management. Eur J Intern Med. 2022 Mar;97:26-31. doi: 10.1016/j.ejim.2021.10.035.

13. De Valle M.B., Av Klinteberg V., Alem N., Olsson R., Björnsson E. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther. 2006 Oct 15;24(8):1187-95. doi: 10.1111/j.1365-2036.2006.03117.x.

14. Shen T., Liu Y., Shang J. et al. Incidence and Etiology of Drug-Induced Liver Injury in Mainland China. Gastroenterology. 2019 Jun;156(8):2230-2241.e11. doi: 10.1053/j.gastro.2019.02.002.

15. Sgro C., Clinard F., Ouazir K. et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002 Aug;36(2):451-5. doi: 10.1053/jhep.2002.34857.

16. Bagheri H., Michel F., Lapeyre-Mestre M., Lagier E., Cambus J.P., Valdiguié P., Montastruc J.L. Detection and incidence of drug-induced liver injuries in hospital: a prospective analysis from laboratory signals. Br J Clin Pharmacol. 2000 Nov;50(5):479-84. doi: 10.1046/j.1365-2125.2000.00282.x.

17. Meier Y., Cavallaro M., Roos M., Pauli-Magnus C., Folkers G., Meier P.J., Fattinger K. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol. 2005 Apr;61(2):135-43. doi: 10.1007/s00228-004-0888-z.

18. Chayanupatkul M., Schiano T.D. Acute Liver Failure Secondary to Drug-Induced Liver Injury. Clin Liver Dis. 2020 Feb;24(1):75-87. doi: 10.1016/j.cld.2019.09.005.@@ Иванова Д.А., Борисов С.Е. Оценка риска и мониторинг гепатотоксических реакций у больных туберкулезом. Туберкулез и болезни легких. 2017;95(9):40-48. doi: 10.21292/2075-1230-2017-95-9-40-48.

19. Ivаnovа D.A., Borisov S.E. Risk assessment and monitoring of hepatotoxic reactions in tuberculosis patients. Tuberculosis and Lung Diseases. 2017;95(9):40-48. (In Russ.) doi: 10.21292/2075-1230-2017-95-9-40-48.

20. Ivanikov I.O., Vinogradova N.N., Krashenkov O.P., Kotselapova E. Yu., Grigorieva Yu.V., Myasnikova E.V., Pikunova I.N. Treatment of the chemotherapy induced hepatotoxicity. Russian Journal of Evidence-Based Gastroenterology. 2020;9(4):7-15. (In Russ.) doi: 10.17116/dokgastro202090417.@@ Иваников И.О., Виноградова Н.Н., Крашенков О.П., Коцелапова Э.Ю., Григорьева Ю.В., Мясникова Е.В., Пикунова И.Н. Острые повреждения печени вследствие химиотерапии и возможности их лечения. Доказательная гастроэнтерология. 2020;9(4):7-15. doi: 10.17116/dokgastro202090417.

21. Wai C.T., Tan B.H., Chan C.L., Sutedja D.S., Lee Y.M., Khor C., Lim S.G. Drug-induced liver injury at an Asian center: a prospective study. Liver Int. 2007 May;27(4):465-74. doi: 10.1111/j.1478-3231.2007.01461.x.

22. Navarro V.J., Barnhart H., Bonkovsky H.L. et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology. 2014 Oct;60(4):1399-408. doi: 10.1002/hep.27317.

23. Polunina T.E., Maev I.V. Medicinal hepatitis. Consilium medicum. Gastroenterology. 2008;1:3-10. (In Rus.)@@ Полунина Т.Е., Маев И.В. Лекарственный гепатит. Consilium medicum. Гастроэнтерология. 2008;1:3-10.

24. Tkachenko P.E., Ivashkin V.T., Maevskaya M.V. [Practical recommendations for the correction of hepatotoxicity induced by antitumor therapy. Practical recommendations RUSSCO, part 2]. Malignant tumours. 2023;13(3s2-2):69-82. (In Russ.) doi: 10.18027/2224-5057-2023-13-3s2-2-69-82.@@ Ткаченко П.Е., Ивашкин В.Т., Маевская М.В. Практические рекомендации по коррекции гепатотоксичности, индуцированной противоопухолевой терапией. Практические рекомендации RUSSCO, часть 2. Злокачественные опухоли. 2023;13(3s2-2):69-82. doi: 10.18027/2224-5057-2023-13-3s2-2-69-82.

25. Galimova S.F. Drug-induced liver injuries (part I). Transplantologiya. The Russian Journal of Transplantation. 2011;(1):13-21. (In Russ.) doi: 10.23873/2074-0506-2011-0-1-13-21.@@ Галимова С.Ф. Лекарственные поражения печени (часть I). Трансплантология. 2011;(1):13-21. doi: 10.23873/2074-0506-2011-0-1-13-21.

26. Lazebnik L.B., Golovanova E.V., Hlynova O.V. et al. Medicinal liver damage in adults. Experimental and Clinical Gastroenterology. 2020;174(2):29-54. (In Russ.) doi: 10.31146/1682-8658-ecg-174-2-29-54.@@ Лазебник Л.Б., Голованова Е.В., Хлынова О.В. и др. Лекарственные поражения печени (ЛПП) у взрослых. Экспериментальная и клиническая гастроэнтерология. 2020;174(2):29-54. doi: 10.31146/1682-8658-ecg-174-2-29-54.

27. Lazebnik L.B., Golovanova E.V., Alekseenko S.A. et al. Medicinal liver damage in adults. Therapy. 2020;6(4(38)):52-76. doi: 10.18565/therapy.2020.5.52-76.@@ Лазебник Л.Б., Голованова Е.В., Алексеенко С.А. и др. Клинические рекомендации: лекарственные поражения печени у взрослых. Терапия. - 2020. - Т. 6, № 4(38). - С. 52-76. doi: 10.18565/therapy.2020.5.52-76.

28. Quintás G., Martínez-Sena T., Conde I., Pareja Ibars E., Kleinjans J., Castell J.V. Metabolomic analysis to discriminate drug-induced liver injury (DILI) phenotypes. Arch Toxicol. 2021 Sep;95(9):3049-3062. doi: 10.1007/s00204-021-03114-z.

29. Ardila-Suárez O.M., Oriz-Benjumea L., Arteta A.A., Guevara-Casallas L.G. Drug-induced liver injury: Relation between the R ratio and histopathology. Rev Gastroenterol Mex (Engl Ed). 2023 Jan-Mar;88(1):19-27. doi: 10.1016/j.rgmxen.2022.03.006.

30. Kobayashi T., Iwaki M., Nogami A., Yoneda M. Epidemiology and Management of Drug-induced Liver Injury: Importance of the Updated RUCAM. J Clin Transl Hepatol. 2023 Oct 28;11(5):1239-1245. doi: 10.14218/JCTH.2022.00067S.

31. Hoofnagle J.H., Björnsson E.S. Drug-Induced Liver Injury - Types and Phenotypes. N Engl J Med. 2019 Jul 18;381(3):264-273. doi: 10.1056/NEJMra1816149.

32. Kleiner D.E., Chalasani N.P., Lee W.M., Fontana R.J., Bonkovsky H.L., Watkins P.B., Hayashi P.H., Davern T.J., Navarro V., Reddy R., Talwalkar J.A., Stolz A., Gu J., Barnhart H., Hoofnagle J.H.; Drug-Induced Liver Injury Network (DILIN). Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology. 2014 Feb;59(2):661-70. doi: 10.1002/hep.26709.

33. Francis P., Navarro V.J. Drug-Induced Hepatotoxicity. 2024 Sep 10. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. PMID: 32491467.

34. Ortega-Alonso A., Andrade R.J. Chronic liver injury induced by drugs and toxins. J Dig Dis. 2018 Sep;19(9):514-521. doi: 10.1111/1751-2980.12612.

35. Tokushige K., Ikejima K., Ono M. et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. Hepatol Res. 2021 Oct;51(10):1013-1025. doi: 10.1111/hepr.13688.

36. Ortega-Alonso A., Stephens C., Lucena M.I., Andrade R.J. Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury. Int J Mol Sci. 2016 May 12;17(5):714. doi: 10.3390/ijms17050714.

37. Fontana R.J., Hayashi P.H., Barnhart H., Kleiner D.E., Reddy K.R., Chalasani N., Lee W.M., Stolz A., Phillips T., Serrano J., Watkins P.B.; DILIN Investigators. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury. Am J Gastroenterol. 2015 Oct;110(10):1450-9. doi: 10.1038/ajg.2015.283.

38. Aithal G.P., Watkins P.B., Andrade R.J. et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011 Jun;89(6):806-15. doi: 10.1038/clpt.2011.58.

39. Mao Y., Ma S., Liu C. et al.; Technology Committee on DILI Prevention, Management, Chinese Medical Biotechnology Association; Study Group on Drug-Induced Liver Disease, Chinese Society of Hepatology, Chinese Medical Association. Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update. Hepatol Int. 2024 Apr;18(2):384-419. doi: 10.1007/s12072-023-10633-7.

40. Chalasani N.P., Maddur H., Russo M.W., Wong R.J., Reddy K.R.; Practice Parameters Committee of the American College of Gastroenterology. ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. Am J Gastroenterol. 2021 May 1;116(5):878-898. doi: 10.14309/ajg.0000000000001259.

41. Björnsson H.K., Björnsson E.S. Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management. Eur J Intern Med. 2022 Mar;97:26-31. doi: 10.1016/j.ejim.2021.10.035.

42. Garcia-Cortes M., Robles-Diaz M., Stephens C., Ortega-Alonso A., Lucena M.I., Andrade R.J. Drug induced liver injury: an update. Arch Toxicol. 2020 Oct;94(10):3381-3407. doi: 10.1007/s00204-020-02885-1.

43. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019 Jun;70(6):1222-1261. doi: 10.1016/j.jhep.2019.02.014.

44. Fontana R.J., Bjornsson E.S., Reddy R., Andrade R.J. The Evolving Profile of Idiosyncratic Drug-Induced Liver Injury. Clin Gastroenterol Hepatol. 2023 Jul;21(8):2088-2099. doi: 10.1016/j.cgh.2022.12.040.

45. Fontana R.J., Liou I., Reuben A., Suzuki A., Fiel M.I., Lee W., Navarro V. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology. 2023 Mar 1;77(3):1036-1065. doi: 10.1002/hep.32689.

46. Gudushauri N., Navarro V.J., Halegoua-De Marzio D. A comprehensive update in herbal and dietary supplement-induced liver injury. Clin Liver Dis (Hoboken). 2024 Jun 21;23(1): e0185. doi: 10.1097/CLD.0000000000000185.

47. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. PMID: 31643176.

48. Devarbhavi H., Aithal G., Treeprasertsuk S., Takikawa H. et al.; Asia Pacific Association of Study of Liver. Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines. Hepatol Int. 2021 Apr;15(2):258-282. doi: 10.1007/s12072-021-10144-3.

49. Björnsson E.S. Clinical management of patients with drug-induced liver injury (DILI). United European Gastroenterol J. 2021 Sep;9(7):781-786. doi: 10.1002/ueg2.12113.

50. Averbukh LD, Turshudzhyan A, Wu DC, Wu GY. Statin-induced Liver Injury Patterns: A Clinical Review. J Clin Transl Hepatol. 2022 Jun 28;10(3):543-552. doi: 10.14218/JCTH.2021.00271.

51. Chirapongsathorn S., Sukeepaisarnjaroen W., Treeprasertsuk S. et al. Characteristics of Drug-induced Liver Injury in Chronic Liver Disease: Results from the Thai Association for the Study of the Liver (THASL) DILI Registry. J Clin Transl Hepatol. 2023 Feb 28;11(1):88-96. doi: 10.14218/JCTH.2021.00479.

52. Wang Q., Huang A., Wang J.B., Zou Z. Chronic Drug-Induced Liver Injury: Updates and Future Challenges. Front Pharmacol. 2021 Mar 8;12:627133. doi: 10.3389/fphar.2021.627133.

53. Weber S., Gerbes A.L. Challenges and Future of Drug-Induced Liver Injury Research-Laboratory Tests. Int J Mol Sci. 2022 May 27;23(11):6049. doi: 10.3390/ijms23116049.

54. Ahmad J., Barnhart H.X., Bonacini M., Ghabril M., Hayashi P.H., Odin J.A., Rockey D.C., Rossi S., Serrano J., Tillmann H.L., Kleiner D.E.; Drug-Induced Liver Injury Network. Value of liver biopsy in the diagnosis of drug-induced liver injury. J Hepatol. 2022 May;76(5):1070-1078. doi: 10.1016/j.jhep.2021.12.043.

55. Roth S.E., Avigan M.I., Bourdet D. et al. Next-Generation DILI Biomarkers: Prioritization of Biomarkers for Qualification and Best Practices for Biospecimen Collection in Drug Development. Clin Pharmacol Ther. 2020 Feb;107(2):333-346. doi: 10.1002/cpt.1571.

56. Rockey D.C., Seeff L.B., Rochon J., Freston J., Chalasani N., Bonacini M., Fontana R.J., Hayashi P.H.; US Drug-Induced Liver Injury Network. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology. 2010 Jun;51(6):2117-26. doi: 10.1002/hep.23577.

57. Kobayashi T., Iwaki M., Nogami A., Yoneda M. Epidemiology and Management of Drug-induced Liver Injury: Importance of the Updated RUCAM. J Clin Transl Hepatol. 2023 Oct 28;11(5):1239-1245. doi: 10.14218/JCTH.2022.00067S.

58. Mironenkova S.E. Application of acetylcysteine as an antidote for paracetamol poisoning in clinical practice. Bulletin of the Chelyabinsk Regional Clinical Hospital. 2022;2(54):28-34. (in Russ.)@@ Мироненкова С.Е. Применение ацетилцистеина в качестве антидота при отравлении парацетамолом в клинической практике Вестник Челябинской областной клинической больницы. 2022. - № 2 (54). - С. 28-34.

59. Li M., Luo Q., Tao Y., Sun X., Liu C. Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review. Front Pharmacol. 2022 Jan 5;12:806249. doi: 10.3389/fphar.2021.806249.

60. Eroglu N., Erduran E., Reis G.P., Bahadır A. Therapeutic effect of N-acetylcysteine on chemotherapy-induced liver injury. Ir J Med Sci. 2020 Nov;189(4):1189-1194. doi: 10.1007/s11845-020-02219-1.

61. WAN Mobin, WANG Lei, WANG Yuming et al. [Expert consensus on the clinical use of Bicyclol]. Clin J Exp Clin Dis. 2014 Dec;8(6).

62. Zhao T.M., Wang Y., Deng Y. et al. Bicyclol Attenuates Acute Liver Injury by Activating Autophagy, Anti-Oxidative and Anti-Inflammatory Capabilities in Mice. Front Pharmacol. 2020 Apr 17;11:463. doi: 10.3389/fphar.2020.00463.

63. Li X., Zhou J., Chen S., Guan M., Wang Y., Zhao L., Ying H., Zhou Y. Role of bicyclol in preventing chemotherapeutic agent-induced liver injury in patients over 60 years of age with cancer. J Int Med Res. 2014 Aug;42(4):906-14. doi: 10.1177/0300060514527058.

64. Chu N.H., Li L., Zhang X., Gu J., Du Y.D., Cai C., Xiao H.P. Role of bicyclol in preventing drug-induced liver injury in tuberculosis patients with liver disease. Int J Tuberc Lung Dis. 2015 Apr;19(4):475-80. doi: 10.5588/ijtld.14.0579.

65. Tang R.L. [Analysis of the efficacy of bicyclol tablets in the treatment of liver injury caused by anti-tuberculosis drug]. Xinxueguanbing Fangzhi Zhishi. 2013;(10):83-85. Chine.

66. Naiqiong W., Liansheng W., Zhanying H., Yuanlin G., Chenggang Z., Ying G., Qian D., Dongchen L., Yanjun Z., Jianjun L. A Multicenter and Randomized Controlled Trial of Bicyclol in the Treatment of Statin-Induced Liver Injury. Med Sci Monit. 2017 Dec 4;23:5760-5766. doi: 10.12659/msm.904090.

67. Niu H., Sanabria-Cabrera J., Alvarez-Alvarez I. et al. Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials. Pharmacol Res. 2021 Feb;164:105404. doi: 10.1016/j.phrs.2020.105404.

68. Naiqiong W., Liansheng W., Zhanying H. et al. A Multicenter and Randomized Controlled Trial of Bicyclol in the Treatment of Statin-Induced Liver Injury. Med Sci Monit. 2017 Dec 4;23:5760-5766. doi: 10.12659/msm.904090.

69. Tang J., Gu J., Chu N. et al. Efficacy and safety of bicyclol for treating patients with idiosyncratic acute drug-induced liver injury: A multicenter, randomized, phase II trial. Liver Int. 2022 Aug;42(8):1803-1813. doi: 10.1111/liv.15290.

70. Bohan T.P., Helton E., McDonald I. et al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology. 2001 May 22;56(10):1405-9. doi: 10.1212/wnl.56.10.1405.

71. Schulte R., Hinson A., Huynh V., Breese E.H., Pierro J., Rotz S., Mixon B.A., McNeer J.L., Burke M.J., Orgel E. Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia. Cancer Med. 2021 Nov;10(21):7551-7560. doi: 10.1002/cam4.4281.

72. Karkhanis J., Verna E.C., Chang M.S., Stravitz R.T., Schilsky M., Lee W.M., Brown R.S. Jr.; Acute Liver Failure Study Group. Steroid use in acute liver failure. Hepatology. 2014 Feb;59(2):612-21. doi: 10.1002/hep.26678.

73. Hu P.F., Wang P.Q., Chen H., Hu X.F., Xie Q.P., Shi J., Lin L., Xie W.F. Beneficial effect of corticosteroids for patients with severe drug-induced liver injury. J Dig Dis. 2016 Sep;17(9):618-627. doi: 10.1111/1751-2980.12383.

74. Tujios S.R., Lee W.M. Acute liver failure induced by idiosyncratic reaction to drugs: Challenges in diagnosis and therapy. Liver Int. 2018 Jan;38(1):6-14. doi: 10.1111/liv.13535.

75. Wan Y.M., Wu J.F., Li Y.H., Wu H.M., Wu X.N., Xu Y. Prednisone is not beneficial for the treatment of severe drug-induced liver injury: An observational study (STROBE compliant). Medicine (Baltimore). 2019 Jun;98(26): e15886. doi: 10.1097/MD.0000000000015886.

76. Fang-JiaoSonga, Hong-LingLiua, YingSuna et al. Prednisolone therapy accelerates recovery of severe drug-induced liver injury: A prospective, randomized controlled study. iLIVER. 2023;2(3):156-162. doi: 10.1016/j.iliver.2023.06.001.

77. Niu H., Ma J., Medina-Caliz I. et al. Potential benefit and lack of serious risk from corticosteroids in drug-induced liver injury: An international, multicentre, propensity score-matched analysis. Aliment Pharmacol Ther. 2023 Apr;57(8):886-896. doi: 10.1111/apt.17373.

78. Björnsson E., Talwalkar J., Treeprasertsuk S., Kamath P.S., Takahashi N., Sanderson S., Neuhauser M., Lindor K. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010 Jun;51(6):2040-8. doi: 10.1002/hep.23588.

79. Björnsson E.S., Bergmann O., Jonasson J.G., Grondal G., Gudbjornsson B., Olafsson S. Drug-Induced Autoimmune Hepatitis: Response to Corticosteroids and Lack of Relapse After Cessation of Steroids. Clin Gastroenterol Hepatol. 2017 Oct;15(10):1635-1636. doi: 10.1016/j.cgh.2017.05.027.

80. Fontana R.J., Liou I., Reuben A., Suzuki A., Fiel M.I., Lee W., Navarro V. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology. 2023 Mar 1;77(3):1036-1065. doi: 10.1002/hep.32689.

81. Wree A., Dechêne A., Herzer K., Hilgard P., Syn W.K., Gerken G., Canbay A. Steroid and ursodesoxycholic Acid combination therapy in severe drug-induced liver injury. Digestion. 2011;84(1):54-9. doi: 10.1159/000322298.

82. Czaja A.J. Difficult treatment decisions in autoimmune hepatitis. World J Gastroenterol. 2010 Feb 28;16(8):934-47. doi: 10.3748/wjg.v16.i8.934.

83. [Diseases of the liver and biliary tract]. / Ed. V.T. Ivashkin. Moscow.: Publishing house “M-Vesti”, 2002. 416 p. (in Russ.)

84. Болезни печени и желчевыводящих путей / Под ред. В.Т. Ивашкина. - М.: Издательский дом «М-Вести», 2002.-416 с.

85. Matveyev A.V. [Hepatoprotectors. Analysis of international studies on drugs of the group of drugs for the liver]. Simferopol: IT «ARIAL». 2013. 382 p. (in Russ.)@@ Матвеев А.В. Гепатопротекторы. Анализ международных исследований по препаратам группы лекарств для печени. Симферополь: ИТ «АРИАЛ». 2013. с. 382.

86. Okovity S.N., Bezborodov N.N., Uleychik S.G., Shulenin S.N. [Hepatoprotectors]. Moscow: GEOTAR-Media. 2010. 112 p. (in Russ.)@@ Оковитый С.Н., Безбородов Н.Н., Улейчик С.Г., Шуленин С.Н. Гепатопротекторы. - М.: ГЭОТАР-Медиа, 2010. - 112 с.

87. Degtyareva I.I., Skrypnik I.N., Nevoyt A.V. et al. Hepatoprotectors-antioxidants in the therapy of patients with chronic diffuse liver diseases. New medical Technologies. 2002;(6):18-23. (in Russ.)@@ Дегтярева И.И., Скрыпник И.Н., Невойт А.В. и др. Гепатопротекторы-антиоксиданты в терапии больных с хроническими диффузными заболеваниями печени // Новые мед. технологии 2002. № 6. С. 18-23.

88. Gillessen A., Schmidt H.H. Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review. Adv Ther. 2020 Apr;37(4):1279-1301. doi: 10.1007/s12325-020-01251-y.

89. Niu H., Sanabria-Cabrera J., Alvarez-Alvarez I., Robles-Diaz M., Stankevičiūtė S., Aithal G.P., Björnsson E.S., Andrade R.J., Lucena M.I. Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials. Pharmacol Res. 2021 Feb;164:105404. doi: 10.1016/j.phrs.2020.105404.

90. Flora K., Hahn M., Rosen H., Benner K. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol. 1998 Feb;93(2):139-43. doi: 10.1111/j.1572-0241.1998.00139.x.

91. Eminzade S., Uraz F., Izzettin F.V. Silymarin protects liver against toxic effects of anti-tuberculosis drugs in experimental animals. Nutr Metab (Lond). 2008 Jul 5;5:18. doi: 10.1186/1743-7075-5-18.

92. Gu J., Tang S.J., Tan S.Y. et al. An open-label, randomized and multi-center clinical trial to evaluate the efficacy of Silibinin in preventing drug-induced liver injury. Int J Clin Exp Med. 2015 Mar 15;8(3):4320-7. PMID: 26064348.

93. Luangchosiri C., Thakkinstian A., Chitphuk S., Stitchantrakul W., Petraksa S., Sobhonslidsuk A. A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury. BMC Complement Altern Med. 2015 Sep 23;15:334. doi: 10.1186/s12906-015-0861-7.

94. Marjani M., Baghaei P., Kazempour Dizaji M., Gorji Bayani P., Fahimi F., Tabarsi P., Velayati A.A. Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial. Iran J Pharm Res. 2016 Winter;15(1):247-52. PMID: 27610165.

95. Zhang S., Pan H., Peng X., Lu H., Fan H., Zheng X., Xu G., Wang M., Wang J. Preventive use of a hepatoprotectant against anti-tuberculosis drug-induced liver injury: A randomized controlled trial. J Gastroenterol Hepatol. 2016 Feb;31(2):409-16. doi: 10.1111/jgh.13070.

96. Heo E., Kim D.K., Oh S.H., Lee J.K., Park J.H., Chung H.S. Effect of Prophylactic Use of Silymarin on Anti-tuberculosis Drugs Induced Hepatotoxicity. Tuberc Respir Dis (Seoul). 2017 Jul;80(3):265-269. doi: 10.4046/trd.2017.80.3.265.

97. Wu H., J. Li, Q. An, S.P. Zhang, L.N. Shen, [Efficacy of silibinin capsules in the prevention of liver injury induced by anti-tuberculosis drugs]. Chin. J. Antituberc. 2017;39 (7):757-760.

98. Ramappa V., Aithal G.P. Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management. J Clin Exp Hepatol. 2013 Mar;3(1):37-49. doi: 10.1016/j.jceh.2012.12.001.

99. Lee C.M., Lee S.S., Lee J.M. et al. Early monitoring for detection of antituberculous drug-induced hepatotoxicity. Korean J Intern Med. 2016 Jan;31(1):65-72. doi: 10.3904/kjim.2016.31.1.65.

100. Abbara A., Chitty S., Roe J.K. et al. Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK. BMC Infect Dis. 2017 Mar 24;17(1):231. doi: 10.1186/s12879-017-2330-z.

101. Marjani M., Fahim F., Sadr M., Kazempour Dizaji M., Moniri A., Khabiri S., Tabarsi P., Velayati A.A. Evaluation of Silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial. Gastroenterol Hepatol Bed Bench. 2019 Spring;12(2):138-142. PMID: 31191838.

102. Asgarshirazi M., Shariat M., Sheikh M. Comparison of efficacy of folic acid and silymarin in the management of antiepileptic drug induced liver injury: a randomized clinical trial. Hepatobiliary Pancreat Dis Int. 2017 Jun;16(3):296-302. doi: 10.1016/s1499-3872(16)60142-x.

103. Vincenzi B., Russo A., Terenzio A. et al. The use of SAMe in chemotherapy-induced liver injury. Crit Rev Oncol Hematol. 2018 Oct;130:70-77. doi: 10.1016/j.critrevonc.2018.06.019.

104. Neri S., Signorelli S.S., Ierna D. et al. Role of Ademetionine (S-Adenosylmethionine) in Cyclosporin-Induced Cholestasis. Clin. Drug Investig. 2002;22:191-195. doi: 10.2165/00044011-200222030-00006.

105. Vincenzi B., Santini D., Frezza A.M., Berti P., Vespasiani U., Picardi A., Tonini G. The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen. Expert Opin Drug Saf. 2011 May;10(3):345-9. doi: 10.1517/14740338.2011.562888.

106. Snegovoy A.V., Larionova V.B., Zeynalova P.A., Manyuk L.V., Kreynina Yu.M., Kagonia L.M. Final results prospective, multicenter program p12-717 (same application in chronic liver disease, conditionality of drug-induced liver injury due to chemotherapy). Journal of N.N. Blokhin Russian Cancer Research Center RAMS. 2016;27(2):142-156. (in Russ.)@@ Снеговой А.В., Ларионова В.Б., Зейналова П.А., Манзюк Л.В., Крейнина Ю.М., Кагония Л.М. Окончательные результаты проспективной многоцентровой программы p12-717 (применение Гептрала при хронической болезни печени, обусловленной лекарственно-индуцированным поражением печени вследствие химиотерапии) // Вестник РОНЦ им. Н.Н. Блохина РАМН. 2016. Т. 27. № 2. С. 142-156.

107. Noureddin M., Sander-Struckmeier S., Mato J.M. Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review. World J Hepatol. 2020 Feb 27;12(2):46-63. doi: 10.4254/wjh.v12.i2.46.

108. Tkachenko P.E., Ivashkin V.T., Maevskaya M.V. [Practical recommendations for the correction of hepatotoxicity induced by antitumor therapy. Practical recommendations RUSSCO, part 2]. Malignant tumours. 2023;13(3s2-2):69-82. (In Russ.) doi: 10.18027/2224-5057-2023-13-3s2-2-69-82.@@ Ткаченко П.Е., Ивашкин В.Т., Маевская М.В. Практические рекомендации по коррекции гепатотоксичности, индуцированной противоопухолевой терапией. Практические рекомендации RUSSCO, часть 2. Злокачественные опухоли. 2023;13(3s2-2):69-82. doi: 10.18027/2224-5057-2023-13-3s2-2-69-82.

109. Maksimova E.V., Kliaritskaia I.L. Hepatic encephalopathy, diagnostics, differential diagnostics and therapy with ornithine. Consilium Medicum. 2018; 20 (12): 110-116. doi: 10.26442/20751753.2018.12.000019.@@ Максимова Е.В., Кляритская И.Л. Печеночная энцефалопатия, диагностика, дифференциальная диагностика и терапия при помощи орнитина. Consilium Medicum. 2018; 20 (12): 110-116. doi: 10.26442/20751753.2018.12.000019.

110. Larionova V.B., Gorozhanskaya E.G. [Prospects for the use of Hepa-Merz (L-ornithine-L-aspartate) for the prevention and treatment of drug-induced liver injury]. Effective pharmacotherapy. Oncology, Hematology and Radiology. 2009; (3): 6-14. (in Russ.)@@ Ларионова В.Б., Горожанская Э.Г. Перспективы применения Гепа-Мерц (L-орнитин-L-аспартат) для профилактики и лечения лекарственного поражения печени. Эффективная фармакотерапия. Онкология, Гематология и Радиология. 2009; (3): 6-14.

111. Lazebnik L.B., Golovanova E.V., Alekseenko S.A. et al. Russian Consensus “Hyperammonemia in Adults”. Experimental and Clinical Gastroenterology. 2019;(12):4-23. (In Russ.) doi: 10.31146/1682-8658-ecg-172-12-4-23.@@ Лазебник Л.Б., Голованова Е.В., Алексеенко С.А. и др. Российский консенсус «Гипераммониемии у взрослых». Экспериментальная и клиническая гастроэнтерология. 2019;(12):4-23. doi: 10.31146/1682-8658-ecg-172-12-4-23.

112. Lang S.M., Ortmann J., Rostig S., Schiffl H. Ursodeoxycholic acid attenuates hepatotoxicity of multidrug treatment of mycobacterial infections: A prospective pilot study. Int J Mycobacteriol. 2019 Jan-Mar;8(1):89-92. doi: 10.4103/ijmy.ijmy_159_18.

113. Yi-Shin Huang. The Therapeutic Efficacy of Ursodeoxy-cholic Acid (UDCA) in Drug-Induced Liver Injury: Results of a Randomized Controlled Trial. Available at: https://www.gastrojournal.org/article/S0016-5085(10)63727-4/pdf (Accessed: 11.02.2021.)

114. Effect of ursodeoxycholic on drug-induced liver injury FAN Shu-bing, FAN Shu-qi (The First of People’s Hospital of Kunming City, Kunming Yunan 650011, China) Jilin Medical Journal. 2011-29.

115. Martsevich S.Yu., Kutishenko N.P., Drozdova L.Yu., Lerman O.V., Nevzorova V.A., Reznik I.I. et al. Effect of ursodeoxycholic acid on the efficacy and safety of statin treatment in patients with the diseases of the liver, gallbladder and/or biliary tract (RAKURS study). Rational Pharmacotherapy in Cardiology. 2014;(10)2:147-52. (In Russ.)@@ Марцевич С.Ю., Кутишенко Н.П., Дроздова Л.Ю., Лерман О.В., Невзорова В.А., Резник И.И. и др. Изучение влияния урсодезоксихолевой кислоты на эффективность и безопасность лечения статинами у больных с заболеваниями печени, желчного пузыря и/или желчевыводящих путей (исследование РАКУРС). Рациональная фармакотерапия в кардиологии. 2014;(10)2:147-52.

116. Voznenko A.A. [Drug-induced liver damage in patients with tuberculosis of the respiratory organs and ways to overcome them]. diss… doc. of medical sciences. Moscow. 2012. 25 p. (in Russ.)@@ Возненко А.А. Лекарственно-индуцированные поражения печени у больных туберкулезом органов дыхания и пути их преодоления: автореф. дисс… кандидата мед. наук. - М., 2012. - 25 с.

117. Zhu S.M. Comparison of the efficacy of different hepatoprotective drugs on the prevention and treatment of liver injury induced by anti-tuberculosis drugs. Chinese Hospital Pharmacy Journal. 2013;33(22)

118. Marpaung B., Tarigan P., Zein L.H., Barus A.P., Soekiman I.: Tuberculostatic combination treatment with INH/RMP/EMB and administration of Essentiale forte for the prevention of liver damage (German). Therapiewoche. 1988;38:734-740.

119. Kuntz E. “Essentielle” Phospholipide in der Hepatologie - 50 Jahre experimentelle und klinishe Erfahrung. Z. Gastroenterol. 1991;29 (Suppl.2):7-13.

120. Djuric-Milosavijevic O. Polyunsaturated phosphatidylcholine (EPL) used to prevent hepatic lesions during the treatment of tuberculosis. Epat. 1982;28:3-9.

121. Hirose S., Morodoni I., Tanaka M., Toyohara H., Sanemotsu Y., Arakawa H., Kawakami K., Toyota M. The prophylactic effects of polyene phosphatidylcholines (EPL) on liver disorders induced by antitubercular drugs (rifampicin, isoniazid). Kiso to Rinsho. 1982;16:4801-4803.

122. Skripnik I.N. Essential phospholipids in the treatment and prevention of drug-induced liver damage. Modern gastroenterology. 2009;4:22-31. (in Russ.)@@ Скрипник И.Н. Эссенциальные фосфолипиды в лечении и профилактике медикаментозных поражений печени. Сучасна гастроентерологiя. 2009;4:22-31.

123. Palgova L.K., Borisova I.V., Zhestkova N.V., Tarasova M.A. Essential phospholipids use in the treatment of drug-induced liver injury in pregnant women. Journal of obstetrics and women’s diseases. 2017;66(2):14-23. (in Russ.) doi: 10.17816/JOWD66214-23.@@ Пальгова Л.К., Борисова И.В., Жесткова Н.В., Тарасова М.А. Применение эссенциальных фосфолипидов в лечении лекарственных поражений печени при беременности. Журнал акушерства и женских болезней. 2017;66(2):14-23. doi: 10.17816/JOWD66214-23.

124. Kucheryavy Yu. A. et al. [Hepatoprotectors: rational aspects of use]. Moscow: Forte Print, 2012. 36 p. (in Russ.)@@ Кучерявый Ю.А. и соавт. Гепатопротекторы: рациональные аспекты применения: учеб. пособие для врачей / М.: Форте Принт, 2012. - 36 с.

125. Vasilenko I. A. et al. Comparative study of hepatoprotective drugs «Essentiale® Forte N», «Phosphogliv®», «Essliver Forte®». RMJ. 2010; 6: 352-354. (in Russ.)@@ Василенко И.А. и соавт. Сравнительное изучение гепатопротекторных препаратов «Эссенциале® Форте Н», «Фосфоглив®», «Эссливер Форте®». РМЖ. 2010; 6: 352-354.

126. Litvitsky P.F. [Pathophysiology]. Textbook - 4th ed. Revised and supplemented. Moscow: GEOTAR-MED, 2007. 497 p. (in Russ.)@@ Литвицкий П.Ф. Патофизиология: Учебник - 4 изд. Переработанное и дополненное. /- М.: ГЭОТАР-МЕД, 2007. - 497 с

127. Martelli et al. Protective effect of phosphatidylcholine on hepatic lipid peroxidation in rats. Med. Sci. Res. 1989;17:996-995.

128. Konopatskova O.M., Averyanova S.V. Accompanying therapy polychemotherapy during breast cancer. Experience of remaxol. P.A. Herzen Journal of Oncology. 2015;4(6):35-37. (In Russ.) doi: 10.17116/onkolog 20154635-37.@@ Конопацкова О.М., Аверьянова С.В. Применение Ремаксола при полихимиотерапии у больных раком молочной железы. Онкология. Журнал им. П.А. Герцена. 2015;4(6):35-37. doi: 10.17116/onkolog20154635-37.

129. Konopatskova O.M., Averyanova S.V. Adjunct therapy during combination chemotherapy for colorectal cancer. P.A. Herzen Journal of Oncology. 2016;5(1):42-46. (In Russ.) doi: 10.17116/onkolog20165142-46.@@ Конопацкова О.М., Аверьянова С.В. Сопроводительная терапия при проведении полихимиотерапии колоректального рака. Онкология. Журнал им. П.А. Герцена. 2016;5(1):42-46. doi: 10.17116/onkolog20165142-46.

130. Matiakin GG, Ivanov VM, Ivanova OV, Sheĭkin MM. Toxicity modifying action of remaxol by treatment of advanced oral cancer. Stomatology. 2013;92(6):12-15. (In Russ.)@@ Матякин Г.Г., Иванов В.М., Иванова О.В., Шейкин М.М. Токсико-модифицирующее действие ремаксола при лечении местно-распространенного рака слизистой полости рта. Стоматология. 2013; 92(6):12-15.

131. Cherenkov V.G., Petrov A.B., Vasilyeva T.M., Strozhenkov M.M. Possibilities of remaxol in prevention of toxic hepatitis during chemotherapy for cancer patients. Voprosy onkologii. 2013;59(3):369-374. (in Russ.)@@ Черенков В.Г., Петров А.Б., Васильева Т.М., Строженков М.М. Возможности ремаксола для профилактики токсических гепатитов при химиотерапии онкологических больных. Вопросы онкологии. 2013; 59(3):369-374.

132. Sas E.I., Grinevich V.B. Multi-component infusion hepatoprotectors for liver damage. Meditsinskiy sovet = Medical Council. 2019;(3):84-88. (In Russ.) doi: 10.21518/2079-701X-2019-3-84-88.@@ Сас Е.И., Гриневич В.Б. Многокомпонентные инфузионные гепатопротекторы при лекарственном поражении печени. Медицинский Совет. 2019;(3):84-88. doi: 10.21518/2079-701X-2019-3-84-88.

133. Sukhanov D.S., Ivanov A.K., Romantsov M.G., Kovalenko A.L. Treatment of hepatotoxic complications of antituberculosis therapy of succinate - containing drugs. RMJ. 2009; 6: 22-25. (in Russ.)@@ Суханов Д.С., Иванов А.К., Романцов М.Г., Коваленко А.Л. Лечение гепатотоксических осложнений сукцинатсодержащими препаратами. РМЖ. 2009;6:22-5.

134. Mordyk A.V., Ivanova O.G., Nagibina L.A., Sitnikova S.V., Marekhina O.A. Drug-induced liver lesions and their management in the manifestations of tuberculosis. Tuberculosis and Lung Diseases. 2015;(9):47-53. (In Russ.)@@ Мордык А.В., Иванова О.Г., Нагибина Л.А., Ситникова С.В., Марьехина О.А. Лекарственные поражения печени и их лечение в клинике туберкулеза. Туберкулез и болезни легких. 2015;(9):47-53.

135. Shevyreva E.V., Ivanov A.K., Sukhanov D.S., Murzina A.A. Remaxol Hepatoprotective Therapy of Patients with Tuberculosis and HIV Infection in Day Unit of Tuberculosis Dispensary. Antibiot Khimioter = Antibiotics and Chemotherapy. 2012;57(7-8):31-37. (In Russ.)@@ Шевырева Е.В., Иванов А.К., Суханов Д.С., Мурзина А.А. Гепатопротекторная терапия ремаксолом у больных туберкулёзом и ВИЧ-инфекцией в дневном стационаре противотуберкулёзного диспансера. Антибиотики и Химиотерапия. 2012;57(7-8):31-37.

136. Sukhanov D.S., Pavlova M.V., Yablonsky P.K., Vinogradova T.I. Comparative Efficacy of Clinical Use of Reamberin, Remaxol and Ademethionine in Patients with Tuberculosis of the Respiratory Organs and Liver Drug-Injury. Antibiot Khimioter = Antibiotics and Chemotherapy. 2013;58(1-2):13-18. (In Russ.)@@ Суханов Д.С., Павлова М.В., Яблонский П.К., Виноградова Т.И. Сравнительная эффективность клинического применения реамберина, ремаксола и адеметионина у больных туберкулёзом органов дыхания с лекарственными поражениями печени. Антибиотики и Химиотерапия. 2013;58(1-2):13-18.

137. Shifman E. M., Khutorskaya N.N., Krugova L.V. et al. Hepatoprotective therapy in HIV-infected pregnant women receiving antiretroviral drugs. Togliatti Medical Council. 2012;(1-2):35-41. (in Russ.)@@ Шифман Е.М., Хуторская Н.Н., Кругова Л.В. и др. Гепатопротекторная терапия у ВИЧ-инфицированных беременных, получающих антиретровирусные препараты. Тольяттинский медицинский консилиум. - 2012. - № 1-2. - С. 35-41.

138. Shih E.V., Sizova O.S., Machova A.A. Hepatoprotectors in combined therapy of onychomycosis. RMJ. 2016;(14):958-963. (in Russ.)@@ Ших Е.В., Сизова О.С., Махова А.А. Возможности применения гепатопротекторов в комбинированной терапии онихомикозов. РМЖ. 2016;(14):958-963.

139. Sizova O.S., Shikh E.V. Possibilities of Taurine in Correcting the Hepatotoxic Effect of Antifungal Drugs in Patients with Onychomycosis. Meditsinskiy sovet = Medical Council. 2012;(9):30-35. (in Russ.)@@ Сизова О.С., Ших Е.В. Возможности Таурина в коррекции гепатотоксического действия противогрибковых препаратов у больных онихомикозом. Медициский совет. 2012;(9):30-35.

140. Koroleva M.V. [Hepatoprotective properties and pharmacodynamics of drugs affecting ametabolite processes in patients with exogenous toxic liver damage]. Diss… med. Science. Volgograd. 2015. (in Russ.)@@ Королева М.В. Гепатопротекторный свойства и фармакодинамика лекарственных средств, влияющих н аметаболичесик процессы у больных с экзогенно- токсическим поражением печени Автореферат дисс. дмн. Волгоград, 2015.

141. Yu Y.C., Mao Y.M., Chen C.W. et al.; Drug-induced Liver Injury (DILI) Study Group; Chinese Society of Hepatology (CSH); Chinese Medical Association (CMA). CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int. 2017 May;11(3):221-241. doi: 10.1007/s12072-017-9793-2.

142. Chalasani N.P., Hayashi P.H., Bonkovsky H.L., Navarro V.J., Lee W.M., Fontana R.J.; Practice Parameters Committee of the American College of Gastroenterology. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014 Jul;109(7):950-66; quiz 967. doi: 10.1038/ajg.2014.131.

143. Chalasani N.P., Hayashi P.H., Bonkovsky H.L., Navarro V.J., Lee W.M., Fontana R.J.; Practice Parameters Committee of the American College of Gastroenterology. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014 Jul;109(7):950-66; quiz 967. doi: 10.1038/ajg.2014.131.

144. FDA Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation. FDA: Silver Spring, MD, 2019.

145. Papay J.I., Clines D., Rafi R., Yuen N., Britt S.D., Walsh J.S., Hunt C.M. Drug-induced liver injury following positive drug rechallenge. Regul Toxicol Pharmacol. 2009 Jun;54(1):84-90. doi: 10.1016/j.yrtph.2009.03.003.

146. Danan G., Benichou C. Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993 Nov;46(11):1323-30. doi: 10.1016/0895-4356(93)90101-6.

147. Benichou C., Danan G., Flahault A. Causality assessment of adverse reactions to drugs - II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993 Nov;46(11):1331-6. doi: 10.1016/0895-4356(93)90102-7.

148. Dakhoul L., Ghabril M., Gu J., Navarro V., Chalasani N., Serrano J.; United States Drug Induced Liver Injury Network. Heavy Consumption of Alcohol is Not Associated With Worse Outcomes in Patients With Idiosyncratic Drug-induced Liver Injury Compared to Non-Drinkers. Clin Gastroenterol Hepatol. 2018 May;16(5):722-729.e2. doi: 10.1016/j.cgh.2017.12.036.

149. Chalasani N., Bonkovsky H.L., Fontana R., Lee W., Stolz A., Talwalkar J., Reddy K.R., Watkins P.B., Navarro V., Barnhart H., Gu J., Serrano J.; United States Drug Induced Liver Injury Network. Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. Gastroenterology. 2015 Jun;148(7):1340-52.e7. doi: 10.1053/j.gastro.2015.03.006.

150. Cajanding R.J.M. MDMA-Associated Liver Toxicity: Pathophysiology, Management, and Current State of Knowledge. AACN Adv Crit Care. 2019 Fall;30(3):232-248. doi: 10.4037/aacnacc2019852.

151. Regev A., Avigan M.I., Kiazand A. et al. Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. J Autoimmun. 2020 Nov;114:102514. doi: 10.1016/j.jaut.2020.102514.

152. Maria V.A., Victorino R.M. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology. 1997 Sep;26(3):664-9. doi: 10.1002/hep.510260319.

153. Núñez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology. 2010 Sep;52(3):1143-55. doi: 10.1002/hep.23716.

154. Ungo J.R., Jones D., Ashkin D., Hollender E.S., Bernstein D., Albanese A.P., Pitchenik A.E. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med. 1998 Jun;157(6 Pt 1):1871-6. doi: 10.1164/ajrccm.157.6.9711039.

155. Wong W.M., Wu P.C., Yuen M.F. et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology. 2000 Jan;31(1):201-6. doi: 10.1002/hep.510310129.

156. Sembera S., Lammert C., Talwalkar J.A. et al. Frequency, clinical presentation, and outcomes of drug-induced liver injury after liver transplantation. Liver Transpl. 2012 Jul;18(7):803-10. doi: 10.1002/lt.23424.

157. Hoofnagle J.H. Hepatic decompensation during direct-acting antiviral therapy of chronic hepatitis C. J Hepatol. 2016 Apr;64(4):763-5. doi: 10.1016/j.jhep.2016.01.007.

158. Obeticholic acid. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NIDDK: Bethesda, MD, 2012.

159. Torshin I. Yu., Gromova O.A., Tikhonova O.V., Zgoda V.G. Hepatoprotective peptides of the drug Laennec. Experimental and Clinical Gastroenterology. 2022;(7):21-30. (In Russ.) doi: 10.31146/1682-8658-ecg-203-7-21-30.@@ Торшин И.Ю., Громова О.А., Тихонова О.В., Згода В.Г. Гепатопротекторные пептиды препарата Лаеннек. Экспериментальная и клиническая гастроэнтерология. 2022;(7):21-30. doi: 10.31146/1682-8658-ecg-203-7-21-30.

160. Gromova O.A., Torshin I. Yu., Maksimov V.A., Chuchalin A.G., Zgoda V.G., Gromov А.N., Tikhonova O.V. Peptides contained in the composition of Laennec that contribute to the treatment of hyperferritinemia and iron overload disorders. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020;13(4):413-425. (In Russ.) doi: 10.17749/2070-4909/farmakoekonomika.2020.070.@@ Громова О.А., Торшин И.Ю., Максимов В.А., Чучалин А.Г., Згода В.Г., Громов А.Н., Тихонова О.В. Пептиды в составе препарата Лаеннек, способствующие устранению гиперферритинемии и перегрузки железом. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2020;13(4):413-425. doi: 10.17749/2070-4909/farmakoekonomika.2020.070.

161. Gromova O.A., Torshin I.Yu., Demidov V.I., Zhidomorov N.Yu., Kalacheva A.G., Bogacheva T.E., Grishina T.R. Experimental medicinal hepatitis. Hepatoprotective e ects of the drug Laennec in models of toxic liver injury with paracetamol or alcohol. Experimental and Clinical Gastroenterology. 2022;(3):86-92. (In Russ.) doi: 10.31146/1682-8658-ecg-199-3-86-92.@@ Громова О.А., Торшин И.Ю., Демидов В.И., Жидоморов Н.Ю., Калачева А.Г., Богачева Т.Е., Гришина Т.Р. Экспериментальный лекарственный гепатит. Гепатопротекторные эффекты препарата Лаеннек на моделях токсического повреждения печени парацетамолом или алкоголем. Экспериментальная и клиническая гастроэнтерология. 2022;(3):86-92. doi: 10.31146/1682-8658-ecg-199-3-86-92.